NASDAQ:PRPO PRECIPIO INC. Starting to trade up on today’s news. Halted up 20% as of writing this.

Precipio Signs First IV-Cell Customer Agreement

GlobeNewswire   “Press Releases”

NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company.(NASDAQ: PRPO), announced today that (AON) of Fort Myers, Florida, has completed its validation of Precipios proprietary IV-Cell culture media, and will adopt the product for use in its clinical cytogenetics laboratory.

The adoption of IV-Cell by industry leader AON demonstrates Precipios ability to identify a critical unmet market need, develop and bring to market a differentiated, high value solution to the customer. Previous launch of HemeScreen testing by AON in, combined with this agreement for IV-Cell serve as validation of Precipios new strategic business model as a specialty cancer diagnostics products company, and its ability to deliver multiple products to the same customer.

Read the entire article:


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist